Virax Biolabs Group Ltd
VRAX0.851USD
+0.006+0.67%
Horário de mercado （ET）Cotações atrasadas em 15 min
3.69MValor de mercado
--P/L TTM
Mais detalhes de Virax Biolabs Group Ltd Empresa
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Informações da empresa
Código da empresaVRAX
Nome da EmpresaVirax Biolabs Group Ltd
Data de listagemJul 14, 2022
CEOMr. James Foster
Número de funcionários19
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 14
EndereçoBiocity Glasgow
CidadeLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalML1 5UH
Telefone4402077887414
Sitehttps://www.viraxbiolabs.com
Código da empresaVRAX
Data de listagemJul 14, 2022
CEOMr. James Foster
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
Investidores
Investidores
Proporção
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
Tipos de investidores
Investidores
Proporção
Individual Investor
6.63%
Hedge Fund
5.88%
Investment Advisor
0.83%
Other
86.66%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
2023Q3
24
636.78K
40.92%
-179.86K
2023Q2
22
639.17K
41.06%
-174.53K
2023Q1
21
797.76K
51.31%
+134.82K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Foster (James)
368.57K
8.49%
+80.58K
+27.98%
Mar 31, 2025
Armistice Capital LLC
228.04K
5.25%
+228.04K
--
Sep 30, 2024
Mccracken (Nigel Ph.D.)
23.33K
0.54%
+23.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
22.43K
0.52%
-15.49K
-40.85%
Mar 31, 2025
Norton (Evan)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Two Sigma Investments, LP
13.63K
0.31%
+13.63K
--
Mar 31, 2025
Citadel Advisors LLC
13.54K
0.31%
+13.54K
--
Mar 31, 2025
HRT Financial LP
13.51K
0.31%
+13.51K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Data
Tipo
Proporção
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
